Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
99.20
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 52.00 - 156.93
Open     -
Vol / Avg. 0.00/4.02M
Mkt cap 4.50B
P/E     -
Div/yield     -
EPS -1.45
Shares 45.37M
Beta 1.53
Inst. own 106%
Aug 4, 2016
Q2 2016 Anacor Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2016
Anacor Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Anacor Pharmaceuticals Inc Annual Shareholders Meeting
May 10, 2016
Q1 2016 Anacor Pharmaceuticals Inc Earnings Release
May 10, 2016
Q1 2016 Anacor Pharmaceuticals Inc Earnings Call
May 5, 2016
Anacor Pharmaceuticals Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -92.08% -74.37%
Operating margin -85.09% -68.43%
EBITD margin - -67.69%
Return on average assets -38.09% -32.07%
Return on average equity -133.71% -93.42%
Employees 110 -
CDP Score - -

Address

1020 E Meadow Cir
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.